Cannabinoids in Treating Parkinson's Disease Symptoms : A Systematic Review of Clinical Studies
Background: Parkinson's disease (PD) is a serious neurodegenerative condition impacting many individuals worldwide. There is a need for new non-invasive treatments of PD. Cannabinoids in the form of cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC) may offer utility as treatment, and our objective was hence to conduct a systematic review regarding the clinical evidence for the efficacy and safety of cannabinoids in treating PD. Methods: Screening, data extraction, and quality assessments were all conducted by multiple reviewers, with discrepancies resolved by consensus. Results: After conducting searches in 4 different databases, 673 articles were screened. Thirteen articles were deemed eligible for inclusion in this review. It was shown that cannabis, CBD, and nabilone (a synthetic form of THC) were capable of consistently improving motor symptoms more than a placebo. All treatments improved various non-motor symptoms, particularly with cannabis improving pain intensity, and CBD improving psychiatric symptoms in a dose-dependent manner. Adverse effects were usually minor, and, in the case of CBD, rare (except at very high doses). Conclusion: Cannabinoids have been shown to safely offer important potential in treating motor symptoms in PD and some non-motor symptoms. More large-scale randomized control trials for specific forms of cannabinoid treatments are required to determine their overall efficacy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:8 |
|---|---|
| Enthalten in: |
Cannabis and cannabinoid research - 8(2023), 5 vom: 07. Okt., Seite 716-730 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Varshney, Karan [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
19GBJ60SN5 |
|---|
| Anmerkungen: |
Date Completed 23.10.2023 Date Revised 03.11.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1089/can.2023.0023 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM357553268 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM357553268 | ||
| 003 | DE-627 | ||
| 005 | 20231226072835.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1089/can.2023.0023 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1191.xml |
| 035 | |a (DE-627)NLM357553268 | ||
| 035 | |a (NLM)37253174 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Varshney, Karan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cannabinoids in Treating Parkinson's Disease Symptoms |b A Systematic Review of Clinical Studies |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.10.2023 | ||
| 500 | |a Date Revised 03.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Background: Parkinson's disease (PD) is a serious neurodegenerative condition impacting many individuals worldwide. There is a need for new non-invasive treatments of PD. Cannabinoids in the form of cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC) may offer utility as treatment, and our objective was hence to conduct a systematic review regarding the clinical evidence for the efficacy and safety of cannabinoids in treating PD. Methods: Screening, data extraction, and quality assessments were all conducted by multiple reviewers, with discrepancies resolved by consensus. Results: After conducting searches in 4 different databases, 673 articles were screened. Thirteen articles were deemed eligible for inclusion in this review. It was shown that cannabis, CBD, and nabilone (a synthetic form of THC) were capable of consistently improving motor symptoms more than a placebo. All treatments improved various non-motor symptoms, particularly with cannabis improving pain intensity, and CBD improving psychiatric symptoms in a dose-dependent manner. Adverse effects were usually minor, and, in the case of CBD, rare (except at very high doses). Conclusion: Cannabinoids have been shown to safely offer important potential in treating motor symptoms in PD and some non-motor symptoms. More large-scale randomized control trials for specific forms of cannabinoid treatments are required to determine their overall efficacy | ||
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Parkinson's disease | |
| 650 | 4 | |a cannabidiol | |
| 650 | 4 | |a cannabis | |
| 650 | 4 | |a clinical studies | |
| 650 | 4 | |a clinical trials | |
| 650 | 4 | |a symptoms | |
| 650 | 4 | |a tetrahydrocannabinol | |
| 650 | 7 | |a Cannabinoids |2 NLM | |
| 650 | 7 | |a Cannabidiol |2 NLM | |
| 650 | 7 | |a 19GBJ60SN5 |2 NLM | |
| 650 | 7 | |a Hallucinogens |2 NLM | |
| 700 | 1 | |a Patel, Akash |e verfasserin |4 aut | |
| 700 | 1 | |a Ansari, Siraaj |e verfasserin |4 aut | |
| 700 | 1 | |a Shet, Pavan |e verfasserin |4 aut | |
| 700 | 1 | |a Panag, Sohan Singh |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cannabis and cannabinoid research |d 2016 |g 8(2023), 5 vom: 07. Okt., Seite 716-730 |w (DE-627)NLM262402297 |x 2378-8763 |7 nnns |
| 773 | 1 | 8 | |g volume:8 |g year:2023 |g number:5 |g day:07 |g month:10 |g pages:716-730 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1089/can.2023.0023 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 8 |j 2023 |e 5 |b 07 |c 10 |h 716-730 | ||